Author/Authors :
Chew, R Faculty of Medicine - University of Queensland - Brisbane - Queensland, Australia , Vickers, M. L. Faculty of Medicine - University of Queensland - Brisbane - Queensland, Australia , Bigby, K Faculty of Medicine - University of Queensland - Brisbane - Queensland, Australia , Chern, B Faculty of Medicine - University of Queensland - Brisbane - Queensland, Australia , Gericke, C Faculty of Medicine - University of Queensland - Brisbane - Queensland, Australia , Seidl, B. Department of Medical Oncology - Redcliffe Hospital - Redcliffe - Queensland, Australia , Hartnett, G. Department of Medical Oncology - Redcliffe Hospital - Redcliffe - Queensland, Australia , Eriksson, L. Herston Health Sciences Library - University of Queensland - Brisbane - Queensland, Australia
Abstract :
Immune checkpoint inhibitors are the most important new medications in oncology and include inhibitors of programmed celldeath protein-1 (PD-1) such as Pembrolizumab, Nivolumab, and Cemiplimab. These anticancer agents prevent tumour immuneevasion and have been associated with a range of immune-related adverse events (irAEs) including those involving the nervoussystem. In this case report and literature review, we present thefirst case of inflammatory myeloradiculitis secondary toPembrolizumab. We also summarise the characteristics, treatment, and outcomes of other cases reported in the literature whichinclude a component of myelitis. Finally, we make general recommendations on management
Keywords :
Inflammatory Myeloradiculitis Secondary , Pembrolizumab , irAEs , PD-1
